№ lp_1_2_21085
File format: docx
Character count: 3160
File size: 43 KB
This document provides a quick reference guide on asthma inhaler choices and dosage instructions for AIR and MART therapies based on LSCMMG asthma guidelines, highlighting age requirements, dosing instructions, and shelf life of different inhalers.
Year:
2025
Note:
Region / City
Topic:
Asthma Treatment
Document Type:
Quick Reference Guide
Organization / Institution:
LSCMMG
Target Audience:
Medical professionals, Patients over 12 years of age
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Version:
1.01.00
Date:
12/14/2017
Originator:
K. Hutchinson
Description of Change:
Added T3 and T17 region fields, Deleted old region fields, Administrative changes
Scope:
One table for all FYs
Frequency of processing:
Provided from the POC only as changes are made to the list
Pharmacy ID (NCPDP) Format:
Char 7
Pharmacy Name Format:
Char 40
DMIS ID Format:
Char 4
Pharmacy NPI (formerly NPI Type 2) Format:
Char 10
Record layout and content:
All fields are variable length and delimited by “|”
Data Manipulation:
Using VLOOKUP, map NCPDP # to DMISID
Updates:
Updates to the table are no more than once a month
Note:
Data joins performed in M2
Region / city:
N/A
Type of document:
Specification document
Target audience:
Professionals involved in the MHS Mart system
Date of approval:
12/14/2017
Context:
Specification document for Pharmacy ID (NCPDP) Reference Table in MHS Mart (M2), detailing data formats, mappings, and updates procedures.
Note:
Year
Theme:
Health Care
Document Type:
Institutional Summary Table
Year:
2017
Note:
Region / City
Subject:
Healthcare data management, inpatient records
Document Type:
Summary/Specification
Agency / Institution:
MHS
Author:
K. Hutchinson
Target Audience:
Healthcare administrators, IT specialists in military health systems
Effective Period:
From 01/29/2008
Year:
2022
Region / City:
N/A
Theme:
Radiology Data Management
Document Type:
Specification
Organization / Institution:
N/A
Author:
S. Keane, B. Ross, Y. Alexander
Target Audience:
MHS Mart Users
Period of Validity:
N/A
Approval Date:
02/05/2022
Modification Date:
N/A
Year:
2018
Region / City:
Global
Topic:
Military Health System (MHS) Data
Document Type:
Specification
Organization / Institution:
Military Health System
Author:
W. Funk, L. Hopkins, K. Hutchinson, B. Ross
Target Audience:
Military Health System personnel, data analysts, IT specialists
Period of Validity:
Ongoing
Approval Date:
08 October 2018
Revision History:
Document updated periodically as per changes in military health data collection and processing protocols.
Change Log:
08 October 2018, 11 July 2017, 9 April 2013, 26 July 2012, 24 February 2012, etc.
Year:
2025
Region / City:
Ste. Genevieve, Missouri
Theme:
Labor Agreement
Document Type:
Contract
Organization / Institution:
UFCW Local 655, St. Genevieve Country Mart, LLC
Author:
UFCW Local 655, St. Genevieve Country Mart, LLC
Target Audience:
Employees of Ste. Genevieve Country Mart
Period of Effectiveness:
September 8, 2025 - September 4, 2028
Approval Date:
September 8, 2025
Amendment Date:
Not specified
Note:
Description
Year:
2023
Region / city:
International
Topic:
Prize nomination
Document type:
Nomination form
Organization:
UNESCO
Author:
UNESCO
Target audience:
Member States, non-governmental organizations
Period of validity:
N/A
Approval date:
N/A
Date of changes:
N/A
Year:
2026
Region / City:
Stanley
Subject:
Invitation for Expression of Interest
Document Type:
Form
Organization / Institution:
FEHD
Author:
Not specified
Target Audience:
Companies interested in the transformation of Stanley Waterfront Mart
Validity Period:
Before 12 March 2026
Approval Date:
Not specified
Modification Date:
Not specified
Year:
2026
Region / City:
Hong Kong
Location:
Stanley Waterfront Mart, Stanley
Document Type:
Expression of Interest Questionnaire
Organ / Institution:
Food and Environmental Hygiene Department (FEHD)
Department Branch:
Environmental Hygiene Branch
Purpose:
Collection of views and capability information from interested parties regarding the transformation and operation of Stanley Waterfront Mart
Submission Deadline:
12 June 2026 6:00 p.m.
Submission Methods:
Email, post, or hand delivery
Submission Email:
[email protected]
Submission Address:
45/F, Queensway Government Offices, 66 Queensway, Hong Kong
Target Respondents:
Companies or organizations interested in developing or operating the market
Key Topics:
Market transformation vision, operation model, financial arrangements, stalls management, food and beverage offerings, retail mix
Proposed Operation Model:
Single Operator Management (SOM) model
Alternative Financial Models Discussed:
Fixed Fee model, Revenue-Sharing model
Information Requested:
Company background, previous development or operation projects within the past ten years, investment expectations, operational cost estimates, return on investment expectations
Market Focus:
Local heritage, culinary experiences, traditional crafts, tourism and local community engagement
Year:
2025
Location:
Dhaka, Bangladesh
Event:
Dhaka Travel Mart
Organizer:
The Bangladesh Monitor
Venue:
Pan Pacific Sonargaon Hotel
Exhibitor:
Information to be filled by participating organization
Stall types:
Pavilion, Corner Stall, General Stall
Payment details:
Registration fees in USD, bank transfer via BRAC Bank Ltd.
Cancellation policy:
Refund conditions specified before January 10, 2025
Title of research:
Automating patient inhaler technique when using pressurised Metered Dose Inhalers: testing the functionality and impact of the aflo™ digital respiratory management platform in a randomised controlled trial in a primary care setting
Type of document:
Participant information sheet
Study design:
Randomised controlled trial
Setting:
Primary care
Target population:
Children aged 5 years or over with a diagnosis of asthma
Inclusion criteria:
Diagnosis of asthma; confirmed suitable by GP; access to smartphone and WIFI/4G; currently prescribed a spacer; adherence or symptom control issues
Intervention:
aflo™ digital respiratory management platform and inhaler device
Control:
Standard care
Study duration:
24 weeks
Appointments:
Three visits (baseline, 12 weeks, 24 weeks)
Procedures:
Questionnaires; inhaler technique demonstration; blood pressure measurement; lung function test; spirometry data access; blood sample collection
Sample collection:
Up to 8 ml blood at first appointment
Funding body:
Respiratory Analytics Ltd
Ethics approval:
West Midlands - Edgbaston Research Ethics Committee; MHRA
Compensation:
Travel reimbursement and £20 voucher
Data handling:
Anonymised data analysis; GP access to results
Note:
Year
Topic:
Asthma, Education, Health Management
Document Type:
Assessment Tool
Target Audience:
School personnel, parents, healthcare providers
Year:
2023
Region / City:
Cambridge, England
Subject:
Respiratory medicine, dry powder inhalers, design optimization
Document Type:
Research article
Organization / Institution:
Cambridge Healthcare Innovations, BnL Pharma Solutions, Owlstone Medical
Author:
Heather Jameson, David Harris, Jacob Harker, Karina Joyce, Helen Samuel, Max Allsworth
Target Audience:
Researchers, engineers, professionals in respiratory medicine and inhaler technology
Period of Validity:
N/A
Approval Date:
N/A
Date of Changes:
N/A
Note:
Year
Subject:
Asthma, COPD, Health
Document Type:
Instructional Guide
Organization / Institution:
Somerset CCG
Target Audience:
Patients with asthma or COPD
Context:
Instructional guide for patients on how to properly use the Accuhaler inhaler, including troubleshooting and common mistakes.
Document type:
Patient information leaflet
Medical device:
Spiromax inhaler
Related conditions:
Asthma; Chronic obstructive pulmonary disease (COPD)
Examples of products:
DuoResp Spiromax; Aerivio Spiromax
Purpose:
Guidance on correct inhaler technique and maintenance
Reassessment interval:
3 months; 6 months; 12 months
Intended audience:
Patients prescribed Spiromax inhalers
Issuing context:
Healthcare professional instruction
Associated resource:
Online video demonstrations
Year:
2026
Region / City:
Nottingham, UK
Subject:
Dry powder inhaler testing, aerodynamic particle size distribution
Document Type:
Research article
Institution:
Copley Scientific Ltd
Authors:
Ben Bradley, Mark Copley
Target Audience:
Scientists and laboratory technicians in pharmaceutical R&D and quality control
Tested Devices:
Symbicort® Turbohaler®
Experimental Methods:
Andersen Cascade Impactor (ACI), Next Generation Impactor (NGI), Fast Screening Andersen (FSA), Fast Screening Impactor (FSI)
Key Variables:
Flow rate rise-time, flow resistance, apparatus volume
Study Purpose:
To match flow rate rise-time profiles of abbreviated and full resolution impactors using a variable volume and flow resistance compensator
Year:
2026
Region / City:
Nottingham and Nottinghamshire, UK
Subject:
Prescription medication update
Document Type:
Patient letter
Organization / Institution:
NHS Nottingham and Nottinghamshire Integrated Care Board
Author:
Dr X
Target Audience:
Patients prescribed Fostair®
Medication:
Fostair® (beclometasone/formoterol) and Proxor® (beclometasone/formoterol)
Purpose:
Inform patients of inhaler switch and guidance on use
Date Issued:
2026-03-11
Year:
Not specified
Region / city:
Not specified
Subject:
Inhaler usage, asthma, COPD
Document type:
Instructional guide
Organization:
Not specified
Author:
Not specified
Target audience:
Patients with asthma and COPD
Effective period:
Not specified
Approval date:
Not specified
Modification date:
Not specified
Year:
2026
Region / City:
International
Topic:
Respiratory health, asthma, COPD
Document type:
Patient information leaflet
Organization / Institution:
Pharmaceutical company / Healthcare provider
Author:
Not specified
Target audience:
Patients prescribed Ellipta inhalers
Medication examples:
Relvar Ellipta, Anoro Ellipta, Incruse Ellipta
Common issues addressed:
Incorrect inhaler technique, dose management
Reference materials:
Video demonstration link provided
Review period:
At least annually
Year:
2020
Region:
Australia
Subject:
Asthma treatment; inhaled corticosteroids; combination therapy
Document type:
Regulatory submission summary
Organization:
Pharmaceutical Benefits Advisory Committee (PBAC)
Company:
Chiesi Australia Pty Ltd
Drug:
Fostair® (Beclometasone dipropionate 100 µg + Formoterol fumarate 6 µg)
Population:
Adults with asthma requiring ICS/LABA therapy
Comparator:
Budesonide/Formoterol (BUD/FOR 200/6) and other ICS/LABA formulations
Approval status:
TGA approved 12 February 2020
Therapy type:
Maintenance and reliever therapy (MART)
Clinical claim:
Non-inferior efficacy and safety compared to BUD/FOR 200/6 MART
Endpoints:
Time to first severe exacerbation, exacerbation rate, FEV1, ACQ score, reliever use
Submission type:
Category 2, Authority Required (Streamlined) listing
Context:
Regulatory source detailing clinical efficacy, safety, and PBS listing considerations for BEC/FOR 100/6 as a combined maintenance and reliever asthma therapy.